Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Clinical trial NCT05328440 · UNKNOWN

Trial details

NCT number: NCT05328440
Sponsor: Henan Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2022-05-20
Primary completion: 2024-06-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.